In today’s recent session, 0.56 million shares of the Akero Therapeutics Inc (NASDAQ:AKRO) have been traded, and its beta is -0.19. Most recently the company’s share price was $47.90, and it changed around $1.54 or 3.32% from the last close, which brings the market valuation of the company to $3.82B. AKRO at last check was trading at a discount to its 52-week high of $58.40, offering almost -21.92% off that amount. The share price’s 52-week low was $17.86, which indicates that the recent value has risen by an impressive 62.71% since then. We note from Akero Therapeutics Inc’s average daily trading volume that its 10-day average is 2.17 million shares, with the 3-month average coming to 1.29 million.
Akero Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 12 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended AKRO as a Hold, whereas 9 deemed it a Buy, and 0 rated it as Underweight.
Akero Therapeutics Inc (NASDAQ:AKRO) trade information
Instantly AKRO has been showing a green trend so far today with a performance of 3.32% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 50.54 on recent trading dayincreased the stock’s daily price by 5.22%. The company’s shares are currently up 72.18% year-to-date, but still up 25.59% over the last five days. On the other hand, Akero Therapeutics Inc (NASDAQ:AKRO) is 16.83% up in the 30-day period. We can see from the shorts that 6.78 million shares have been sold at a short interest cover period of 5.11 day(s).
The consensus price target as assigned by Wall Street analysts is $45, which translates to bulls needing to decrease their stock price by -6.44% from its current value. Analyst projections state that AKRO is forecast to be at a low of $38 and a high of $56.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -5.28%. Akero Therapeutics Inc earnings are expected to increase by -3.28% in 2025, but the outlook is negative -8.83% per year for the next five years.
AKRO Dividends
Akero Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-May-11.
Akero Therapeutics Inc (NASDAQ:AKRO)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.38% of Akero Therapeutics Inc shares, and 109.28% of them are in the hands of institutional investors. The stock currently has a share float of 110.80%. Akero Therapeutics Inc stock is held by 330.0 institutions, with JANUS HENDERSON GROUP PLC being the largest institutional investor. By 2024-06-30, it held 9.9425% of the shares, which is about 6.88 million shares worth $161.28 million.
BLACKROCK INC., with 8.0778% or 5.59 million shares worth $131.06 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund and iShares Trust-iShares Russell 2000 ETF were the top two Mutual Funds as of Jan 31, 2025 . The former held 4.07 shares worth $193.95 million, making up 5.11% of all outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held roughly 1.96 shares worth around $93.51 million, which represents about 2.46% of the total shares outstanding.
